Loading…

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

meRfi® AI Chat

Bacillus subtilis + Bifidobacterium bifidum + Bifidobacterium breve + Bifidobacterium longum infantis + Bifidobacterium longum + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactiplantibacillus plantarum + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Lactobacillus helveticus + Lactococcus lactis lactis + Ligilactobacillus salivarius + Streptococcus thermophilus & Major depressive disorder / Major Depression / Depressive episode (MDD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

NCT03893162
demonstrated good acceptability and tolerability, and the estimated effect sizes for key clinical outcomes support further evaluation of probiotics as an adjunctive treatment for individuals with major depressive disorder in a definitive efficacy trial (1)

References

(1) Nikolova et al. 2023 JAMA Psychiatry 80(8): 842-847

see also:
Major depressive disorder / Major Depression / Depressive episode (MDD) & Drugs/Treatments
[Probiotics (living agents) & Major depressive disorder / Major Depression / Depressive episode (MDD)](brain://ULr2YzoFrkOwXe0D2aPpFA/ProbioticsLivingAgentsMajorDepress…

References (Sources)

Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial
Nikolova et al. 2023 JAMA Psychiatry 80(8): 842-847

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!